news
Aurobindo Pharma has taken a significant strategic step to further strengthen its position in the domestic formulations market by acquiring the non-oncology formulations business of Maharashtra-based Khandelwal Laboratories for ₹325 crore. The acquisition has been completed through its wholly owned subsidiary, Auro Pharma Limited.
The company announced that the transaction has come into effect from Thursday. With this acquisition, Aurobindo Pharma aims to reinforce its presence in the pain management and anti-infective segments of the domestic market. Khandelwal Laboratories’ portfolio includes 23 well-established branded pharmaceutical products in India.
Comments (0)
No comments yet
Be the first to comment!